• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Why Vuzix Shares Are Trading Higher By Around 15%; Here Are 20 Stocks Moving Premarket

    6/20/24 8:22:52 AM ET
    $ASLN
    $ASNS
    $BILI
    $DXF
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Telecommunications Equipment
    Telecommunications
    Get the next $ASLN alert in real time by email

    Shares of Vuzix Corporation (NASDAQ:VUZI) rose sharply in today's pre-market trading after the company disclosed a strategic partnership with Avegant to develop optimized waveguide optical modules for use in future AI-enabled smart glasses.

    Vuzix shares jumped 15% to $1.53 in the pre-market trading session.

    Here are some other stocks moving in pre-market trading.

    Gainers

    • SMX (Security Matters) Public Limited Company (NASDAQ:SMX) rose 109.8% to $0.2497 in pre-market trading after jumping 19% on Tuesday.
    • Selina Hospitality PLC (NASDAQ:SLNA) gained 46.9% to $0.1024 in pre-market trading after declining 7% on Tuesday.
    • Tempest Therapeutics, Inc. (NASDAQ:TPST) shares rose 44.5% to $4.12 in pre-market trading. Tempest will report new data from global randomized combination study of Amezalpat (TPST-1120) in first-line hepatocellular carcinoma on June 20.
    • Nexalin Technology, Inc. (NASDAQ:NXL) gained 27.8% to $1.33 in pre-market trading. Nexalin Technology shares jumped around 38% on Tuesday after the company was awarded a US patent on ‘Transcranial alternating current dynamic frequency stimulation (TACS) method for Alzheimers and Dementia.’
    • Presto Automation Inc. (NASDAQ:PRST) shares climbed 19.7% to $0.0880 in pre-market trading after falling around 5% on Tuesday.
    • Molecular Partners AG (NASDAQ:MOLN) shares rose 19.5% to $9.50 in pre-market trading after gaining 9% on Tuesday.
    • Griid Infrastructure Inc. (NASDAQ:GRDI) rose 17.7% to $0.6598 in pre-market trading after falling more than 10% on Tuesday.
    • ASLAN Pharmaceuticals Limited (NASDAQ:ASLN) shares gained 14.7% to $0.3581 in pre-market trading after dipping 13% on Tuesday.
    • Bilibili Inc. (NASDAQ:BILI) shares climbed 8% to $17.47 in pre-market trading. On Tuesday, JP Morgan analyst Daniel Chen upgraded Bilibili from Neutral to Overweight and announced a $21 price target.

    Losers

    • NLS Pharmaceutics AG (NASDAQ:NLSP) shares fell 22% to $0.2107 in pre-market trading after jumping 82% on Tuesday.
    • La Rosa Holdings Corp. (NASDAQ:LRHC) shares fell 17.2% to $1.48 in pre-market trading. La Rosa Holdings shares jumped 72% on Tuesday after the company entered a non-binding letter of intent to acquire a controlling interest in Red Door Title.
    • Kaival Brands Innovations Group, Inc (NASDAQ:KAVL) shares declined 15.5% to $3.80 in pre-market trading after gaining 8% on Tuesday.
    • Huize Holding Limited (NASDAQ:HUIZ) shares fell 15% to $0.85 in pre-market trading.
    • Actelis Networks, Inc. (NASDAQ:ASNS) fell 14.2% to $1.82 in pre-market trading. Actelis Networks shares jumped 84% on Tuesday after the company announced an agreement to serve as Carahsoft’s public sector distributor.
    • SRIVARU Holding Limited (NASDAQ:SVMH) shares fell 13.3% to $0.2160 in pre-market trading. SRIVARU, last week, announced it will begin accepting paid reservations and bookings for its flagship product, the PRANA 2.0, on June 16th.
    • Virios Therapeutics Inc (NASDAQ:VIRI) shares declined 12.1% to $0.22 in pre-market trading.
    • Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) shares dipped 9% to $2.66 in pre-market trading after dipping over 14% on Tuesday.
    • Dunxin Financial Holdings Limited (NASDAQ:DXF) shares fell 9.4% to $0.1950 in pre-market trading after dipping 17% on Tuesday.
    • Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) fell 6% to $5.96 in pre-market trading after the company rejected unsolicited takeover bids, citing undervaluation.

    Now Read This: Investor Sentiment Improves After S&P 500 Hits Another Record Close On Tuesday

    Get the next $ASLN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ASLN
    $ASNS
    $BILI
    $DXF

    CompanyDatePrice TargetRatingAnalyst
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Sector Outperform → Sector Perform
    Scotiabank
    Tempest Therapeutics Inc.
    $TPST
    4/10/2025Buy → Neutral
    H.C. Wainwright
    Bilibili Inc.
    $BILI
    11/8/2024Neutral → Buy
    Daiwa Securities
    Vanda Pharmaceuticals Inc.
    $VNDA
    10/31/2024$18.00Buy
    H.C. Wainwright
    Bilibili Inc.
    $BILI
    10/3/2024Outperform → Neutral
    Daiwa Securities
    Bilibili Inc.
    $BILI
    9/26/2024$16.50 → $22.60Neutral → Buy
    Goldman
    Bilibili Inc.
    $BILI
    9/25/2024$15.00 → $20.00Equal-Weight
    Morgan Stanley
    Bilibili Inc.
    $BILI
    8/23/2024$14.00 → $19.00Equal Weight → Overweight
    Barclays
    More analyst ratings

    $ASLN
    $ASNS
    $BILI
    $DXF
    SEC Filings

    See more
    • SEC Form 6-K filed by SMX (Security Matters) Public Limited Company

      6-K - SMX (Security Matters) Public Ltd Co (0001940674) (Filer)

      5/8/25 4:00:26 PM ET
      $SMX
      Industrial Machinery/Components
      Technology
    • SEC Form 10-Q filed by Vanda Pharmaceuticals Inc.

      10-Q - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

      5/8/25 7:06:13 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Vanda Pharmaceuticals Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Vanda Pharmaceuticals Inc. (0001347178) (Filer)

      5/7/25 4:07:33 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    $ASNS
    $BILI
    $DXF
    Leadership Updates

    Live Leadership Updates

    See more
    • Salarius Pharmaceuticals Merger Partner, Decoy Therapeutics, Appoints Renowned MIT Professor Robert S. Langer to its Scientific Advisory Board

      CAMBRIDGE, Mass. and HOUSTON, April 16, 2025 (GLOBE NEWSWIRE) -- Decoy Therapeutics, Inc. (Decoy), a privately held preclinical biopharmaceutical company engineering the next generation of peptide conjugate therapeutics, announces that Massachusetts Institute of Technology (MIT) Professor and Moderna co-founder Robert S. Langer, ScD will join the company's Scientific Advisory Board (SAB) upon the successful completion of Decoy's merger with Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX). As announced on January 13, 2025, Decoy and Salarius Pharmaceuticals signed a definitive agreement under which Decoy Therapeutics will merge with a wholly owned subsidiary of Salarius Pharmaceuticals, with t

      4/16/25 8:00:00 AM ET
      $SLRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Nexalin Technology Welcomes General Wesley Clark to Military & Government Advisory Board

      HOUSTON, TX, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (NASDAQ:NXL, NXLIW)) (the "Company" or "Nexalin") the leader in Deep Intracranial Frequency Stimulation (DIFS™) of the brain, is honored to announce that General Wesley K. Clark (Ret.), former NATO Supreme Allied Commander Europe, has joined its Military & Government Advisory Board. General Clark will collaborate with esteemed members David F. Lasseter, former Deputy Assistant Secretary of Defense for Policy, and William A. Hudson, Jr., former Acting General Counsel to the Department of Veterans Affairs, to advance Nexalin's innovative neurostimulation solutions within U.S. military and government sectors. The Company'

      2/26/25 8:30:00 AM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Actelis Networks Appoints Leading Industry Expert Julie Kunstler as Board Member

      FREMONT, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced the appointment of Julie Kunstler as an independent director to its Board of Directors, effective immediately. Kunstler brings over three decades of experience in the communications components, broadband access equipment sectors, and strategic corporate positioning, along with public company board experience. Kunstler currently serves on the board of Ethernity Networks Ltd., a company traded on the London Stock Exchange, and previously served on the

      2/13/25 4:30:00 PM ET
      $ASNS
      Telecommunications Equipment
      Telecommunications

    $ASLN
    $ASNS
    $BILI
    $DXF
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • CEO, interim CFO La Rosa Joseph was granted 6,594,718 shares (SEC Form 4)

      4 - La Rosa Holdings Corp. (0001879403) (Issuer)

      4/23/25 4:05:38 PM ET
      $LRHC
      Real Estate
      Finance
    • SEC Form 3 filed by new insider Marks Gideon

      3 - ACTELIS NETWORKS INC (0001141284) (Issuer)

      3/24/25 6:05:13 AM ET
      $ASNS
      Telecommunications Equipment
      Telecommunications
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $ASLN
    $ASNS
    $BILI
    $DXF
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Sr. VP - Quality, Regulatory Shelton Carolyn Hamby bought $13,200 worth of shares (6,000 units at $2.20) (SEC Form 4)

      4 - Nexalin Technology, Inc. (0001527352) (Issuer)

      3/13/25 4:52:26 PM ET
      $NXL
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • President and CEO Polymeropoulos Mihael Hristos bought $50,150 worth of shares (10,000 units at $5.01), increasing direct ownership by 0.44% to 2,295,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      3/6/25 5:53:21 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President and CEO Polymeropoulos Mihael Hristos bought $50,200 worth of shares (10,000 units at $5.02), increasing direct ownership by 0.44% to 2,285,731 units (SEC Form 4)

      4 - Vanda Pharmaceuticals Inc. (0001347178) (Issuer)

      3/5/25 5:19:35 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    $ASNS
    $BILI
    $DXF
    Press Releases

    Fastest customizable press release news feed in the world

    See more

    $ASLN
    $ASNS
    $BILI
    $DXF
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $ASLN
    $ASNS
    $BILI
    $DXF
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $ASLN
    $ASNS
    $BILI
    $DXF
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • Actelis Networks Receives New Order to Support Rail Infrastructure Modernization in Northern Ireland

      FREMONT, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced it has received a new order to support railway modernization and digitization initiatives in Northern Ireland. The order, placed through the Kenton Group, a long-time Actelis partner, will deploy Actelis' advanced networking technology trackside to enable next-generation digital rail operations. This infrastructure enhancement delivers secure, high-performance connectivity that supports critical IoT applications including automated signaling systems,

      5/8/25 8:30:00 AM ET
      $ASNS
      Telecommunications Equipment
      Telecommunications
    • Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

      Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new g

      5/7/25 4:01:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • La Rosa Holdings Corp. Reports Strong Q1 2025 Growth at Celebration, FL and BF Prime, Puerto Rico Offices Driven by Increased Agent Count, Revenue, and Transactions

      Celebration, FL, May 07, 2025 (GLOBE NEWSWIRE) -- La Rosa Holdings Corp. (NASDAQ:LRHC) ("La Rosa" or the "Company"), a real estate and PropTech company, today announced strong growth for the first quarter ended March 31, 2025, at two of its fastest-growing brokerages; branch office of La Rosa Realty LLC ("Celebration office") in Celebration, Florida, and BF Prime LLC ("BF Prime") in Carolina, Puerto Rico. At the Celebration office, the agent base expanded by 412 agents year-over-year in the first quarter of 2025. This growth drove a 101% year-over-year increase in transaction volume in the first quarter of 2025 and an 86% year-over-year increase in revenue to $3.4 million for the first qu

      5/7/25 8:00:00 AM ET
      $LRHC
      Real Estate
      Finance
    • Tempest Therapeutics downgraded by Scotiabank

      Scotiabank downgraded Tempest Therapeutics from Sector Outperform to Sector Perform

      4/10/25 8:50:49 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Tempest Therapeutics downgraded by H.C. Wainwright

      H.C. Wainwright downgraded Tempest Therapeutics from Buy to Neutral

      4/10/25 8:03:29 AM ET
      $TPST
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bilibili upgraded by Daiwa Securities

      Daiwa Securities upgraded Bilibili from Neutral to Buy

      11/8/24 11:09:24 AM ET
      $BILI
      EDP Services
      Technology
    • Amendment: SEC Form SC 13D/A filed by Kaival Brands Innovations Group Inc.

      SC 13D/A - Kaival Brands Innovations Group, Inc. (0001762239) (Subject)

      12/12/24 7:22:30 PM ET
      $KAVL
      Other Consumer Services
      Consumer Discretionary
    • Amendment: SEC Form SC 13G/A filed by NLS Pharmaceutics Ltd.

      SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

      11/21/24 4:01:13 PM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by NLS Pharmaceutics Ltd.

      SC 13G/A - NLS Pharmaceutics Ltd. (0001783036) (Subject)

      11/14/24 7:27:23 PM ET
      $NLSP
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-6) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for PONVORY issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug PONVORY (SUPPL-5) with active ingredient PONESIMOD has changed to 'Approval' on 06/05/2024. Application Category: NDA, Application Number: 213498, Application Classification: Labeling

      6/17/24 12:07:18 AM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for FANAPT issued to VANDA PHARMS INC

      Submission status for VANDA PHARMS INC's drug FANAPT (SUPPL-23) with active ingredient ILOPERIDONE has changed to 'Approval' on 04/02/2024. Application Category: NDA, Application Number: 022192, Application Classification: Efficacy

      4/3/24 4:12:36 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $ASLN
    $ASNS
    $BILI
    $DXF
    Financials

    Live finance-specific insights

    See more
    • Vanda Pharmaceuticals Reports First Quarter 2025 Financial Results

      Fanapt® Q1 2025 total prescriptions (TRx) increased 14% compared to Q1 2024Fanapt® Q1 2025 new to brand prescriptions (NBRx) increased nearly threefold compared to Q1 2024Bysanti™ (milsaperidone) NDA for bipolar I disorder and schizophrenia accepted for filing; PDUFA target action date of February 21, 2026Tradipitant NDA for motion sickness accepted for filing; PDUFA target action date of December 30, 2025Imsidolimab BLA in generalized pustular psoriasis expected to be submitted in 2025WASHINGTON, May 7, 2025 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (NASDAQ:VNDA) today announced financial and operational results for the first quarter ended March 31, 2025. "Vanda has entered a new g

      5/7/25 4:01:00 PM ET
      $VNDA
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Actelis Networks to Report First Quarter 2025 Results on May 13, 2025

      FREMONT, Calif., May 06, 2025 (GLOBE NEWSWIRE) -- Actelis Networks, Inc. (NASDAQ:ASNS) ("Actelis" or the "Company"), a market leader in cyber-hardened, rapid deployment networking solutions for IoT and broadband applications, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Tuesday, May 13, 2025. About Actelis Networks, Inc. Actelis Networks, Inc. (NASDAQ:ASNS) is a market leader in hybrid fiber-copper, cyber-hardened networking solutions for rapid deployment in wide-area IoT applications, including government, ITS, military, utility, rail, telecom, and campus networks. Actelis' innovat

      5/6/25 8:40:00 AM ET
      $ASNS
      Telecommunications Equipment
      Telecommunications
    • Bilibili Inc. to Report First Quarter 2025 Financial Results on Tuesday, May 20, 2025

      SHANGHAI, May 06, 2025 (GLOBE NEWSWIRE) -- Bilibili Inc. ("Bilibili" or the "Company") (NASDAQ:BILI), an iconic brand and a leading video community for young generations in China, today announced that it will report its first quarter 2025 unaudited financial results on Tuesday, May 20, 2025, before the open of U.S. markets. The Company's management will host an earnings conference call at 8:00 AM U.S. Eastern Time on May 20, 2025 (8:00 PM Beijing/Hong Kong Time on May 20, 2025). Details for the conference call are as follows: Event Title:Bilibili Inc. First Quarter 2025 Earnings Conference CallRegistration Link:https://register-conf.media-server.com/register/BI04e567ee2b7348e0bea

      5/6/25 6:00:00 AM ET
      $BILI
      EDP Services
      Technology